Pharmaceutical Technology on MSN
Regeneron signs $2.32BN deal with Parabilis for Helicon conjugates
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results